Nomura's Stock Picks Face Scrutiny

While Nomura has flagged Dr. Reddy's Laboratories, Cipla, and Crompton Greaves Consumer Electricals for significant upside potential with 'Buy' ratings, a closer look reveals critical challenges alongside growth prospects. This analysis delves into the competitive landscape, margin sustainability, and execution hurdles that investors should consider.

Valuation Under Scrutiny

Nomura's targets for these companies suggest considerable upside: ₹1,600 for Dr. Reddy's (26% gain), ₹1,510 for Cipla (17%), and ₹335 for Crompton Greaves (18%). These forecasts rely on sustained growth and market share gains. Current valuations offer varied signals. Dr. Reddy's trades at a trailing twelve-month (TTM) P/E of 19.01, below its sector average of 23.87. Cipla's P/E is around 27.64, and Crompton Greaves stands at 39.65, higher than peers like Havells India (44.55) but within a range reflecting growth expectations. The broader Indian pharmaceutical sector sees P/E ratios ranging widely, with companies like Divi's Laboratories trading at a P/E of 71.85.

Catalysts and Execution Hurdles

For Dr. Reddy's, Nomura forecasts double-digit revenue growth fueled by expected gross margins of 50-55% and EBITDA margins near 20%. A key growth driver is the planned launch of generic Semaglutide in Canada, entering the substantial GLP-1 market. This move faces competition from rivals like Sun Pharmaceutical Industries and Cipla, as well as the originator, Novo Nordisk. Cipla's strategy for US market recovery centers on launching four respiratory products and one peptide in FY27, targeting a $1 billion revenue run-rate. However, its FY26 EBITDA margin of 21.0% missed guidance, and recent US sales dipped due to regulatory issues and delayed approvals. Crompton Greaves is projected to see 14% growth in FY27 from demand and new areas like Solar and Wires. Yet, the company posted a ₹533.93 crore loss in Q4 FY26, following three profitable quarters, indicating potential execution hurdles and immediate cost pressures.

The Bear Case: Margin Squeeze and Competitive Threats

Risks temper the optimistic forecasts. Crompton Greaves faces potential margin compression from 'steep near-term cost pressures and investments into new categories.' Nomura expects margins to normalize by FY28. Despite market share gains and price increases, passing full costs to consumers remains difficult. In pharmaceuticals, generic competition is increasing, especially in profitable areas like GLP-1s. Dr. Reddy's, despite its Canadian Semaglutide launch, confronts strong global and domestic rivals like Sun Pharma and Cipla. Cipla's US operations have suffered from regulatory setbacks, including US FDA observations that halted Lanreotide sales and delayed Advair launches, impacting short-term profits. The company's success hinges on timely approvals and product launches in a tough US market. Cipla's FY26 EBITDA margin of 21.0% also missed its 24.0% guidance.

Sectoral Headwinds and Analyst Views

The Indian pharmaceutical sector faces broader challenges, despite recent resilience. The Nifty Pharma index showed gains recently. However, US market growth is predicted to slow to 3-5% in FY2026 from nearly 10% in FY2025 due to global issues and regulatory uncertainty. Dr. Reddy's Q4 FY26 net profit dropped 86.2% year-on-year, influenced by shelf adjustments and price dips. Analyst sentiment on Dr. Reddy's is mixed: 6 rate it 'strong buy', 11 'buy', and 8 'sell'. For Crompton Greaves, the consumer durables sector's sensitivity to economic conditions and consumer spending adds another layer of risk, although Nomura points to summer demand.

Future Projections and Key Watch-Ons

Nomura's targets assume successful execution of growth plans. Dr. Reddy's is expected to see improved earnings from India and ex-US markets. Cipla's management aims for double-digit India growth and a US quarterly revenue run-rate climb from $150 million to $250 million by Q4 FY27. Crompton Greaves is forecast to reach normalized margins by FY28. Investors should monitor Dr. Reddy's Semaglutide launch execution and competitive reactions. For Cipla, ongoing US market penetration and new product launch success are vital. Crompton Greaves' ability to control costs, advance its premiumization strategy, and grow new segments will shape its margins. Ultimately, navigating regulations and competition will determine if Nomura's price targets are met.